Andrew Cheng
Vermögen: 621 174 $ am 31.05.2026
Vermögen: 621 174 $ am 31.05.2026
Andrew Cheng is currently an Independent Director at Vera Therapeutics, Inc. since 2017 and a Director at Boys & Girls Clubs of Metro Los Angeles.
Formerly, Dr. Cheng was President, Chief Executive Officer & Director at Akero Therapeutics, Inc. from 2018 to 2025; Independent Director at Arbutus Biopharma Corp.
from 2019 to 2022; Director at Syntimmune, Inc.; Director at Global Virus Network; Non-Executive Director at MorphoSys AG from 2022 to 2024; and Chief Medical Officer & Executive Vice President at Gilead Sciences, Inc. in 2018.
Education includes an undergraduate degree from The Johns Hopkins University in 1988 and a doctorate from Columbia University College of Physicians & Surgeons in 1996.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.05.2026 | 17 488 ( 0,02 % ) | 621 174 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| VERA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.05.2017 |
Boys & Girls Clubs of Metro Los Angeles
Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Operates as a Non-profit organization that provides proven programming services | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Vorstandsvorsitzender | 09.12.2025 |
| MORPHOSYS AG | Direktor/Vorstandsmitglied | 06.06.2024 |
| ARBUTUS BIOPHARMA CORPORATION | Direktor/Vorstandsmitglied | 25.05.2022 |
| GILEAD SCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 07.09.2018 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Arbutus Biopharma Corp.
Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Health Technology |
MorphoSys AG
MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Global Virus Network
Global Virus Network Miscellaneous Commercial ServicesCommercial Services Researches on essential and critical defense against viral disease | Commercial Services |
Columbia University College of Physicians & Surgeons
Columbia University College of Physicians & Surgeons Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akero Therapeutics, Inc.
Akero Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for patients with metabolic diseases | Health Technology |
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Boys & Girls Clubs of Metro Los Angeles
Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Operates as a Non-profit organization that provides proven programming services | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen